Literature DB >> 8056994

Isoniazid and antidepressants: is there cause for concern?

F K Judd1, A M Mijch, A Cockram, T R Norman.   

Abstract

The antituberculous drug isoniazid has weak monoamine oxidase inhibiting properties. Drug and dietary restrictions generally applied to the use of monoamine oxidase inhibitors (MAOI) have not been routinely recommended with its use. Here we report three cases in which antidepressant drugs and isoniazid were co-administered. In two, adverse events, possibly due to an interaction between the drugs prescribed are described. We suggest that the combination of isoniazid and antidepressants be used with caution until further data are accumulated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056994

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

Review 1.  Serotonin syndrome and drug combinations: focus on MAOI and RIMA.

Authors:  S E Hilton; H Maradit; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Treatment of Comorbid Tuberculosis and Depression.

Authors:  Adam J. Trenton; Glenn W. Currier
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-12

4.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.